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BACKGROUND. Docetaxel induces an anti-tumor response in men with advanced prostate
cancer (PCa); however, the side effects associated with docetaxel treatment can be severe,
resulting in discontinuation of therapy. Thus, identification of an effective adjuvant therapy to
allow lower doses of docetaxel is needed. Advanced PCa is typically accompanied by skeletal
metastasis. Receptor activator of NFkB ligand (RANKL) is a key pro-osteoclastic factor.
Targeting RANKL decreases establishment and progression of PCa growth in bone in murine
models.
METHODS. The efficacy of inhibiting RANKL, using a recombinant soluble RANK
extracellular domain fused with the immunoglobulin Fc domain (RANK-Fc), was tested as
an adjuvant therapy with docetaxel for PCa bone metastasis in a murine intra-tibial model.
RESULT. The combination of RANK-Fc and docetaxel reduced tumor burden in bone greater
than either treatment alone.
CONCLUSION. The combination of docetaxel with a RANKL-inhibiting agent merits further
investigation for treatment of advance PCa. Prostate 68: 820–829, 2008. # 2008 Wiley-Liss, Inc.
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INTRODUCTION
Prostate cancer (PCa) is the most commonly dia-
gnosed cancer and is the third leading cause of cancer-
related deaths of American men [1]. In early stages,
it responds to androgen-withdrawal treatment. How-
ever, as the disease progresses, it becomes independent
of hormone regulation and the cancer becomes resistant
to treatments.
Docetaxel is currently one of the most effective
treatments for PCa [2–5]. In combination with pre-
dnisone, docetaxel is indicated for the treatment
of patients with androgen-independent (hormone-
refractory), metastatic PCa [6]. Docetaxel is a member
of the taxane class of chemotherapy drugs, which
inhibit cancer cell growth by stopping cell division. The
primary mechanism of action of taxanes is to stabilize
microtubules and prevent their disassembly. Since
the reorganization of microtubules is essential to cell
division, disruption of this dynamic causes the cells to
arrest in the G2 phase of the cell cycle [7].
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Although taxanes are initially an effective way to
treat advanced PCa, their side effects can be debilitating
and include localized erythema of the extremities with
edema followed by desquamation, severe neuropathy,
fatigue, and weakness [8]. When these symptoms
occur, docetaxel doses must be reduced or stopped
[8,9], leading to disease progression.
Virtually all patients with advanced PCa develop
debilitating and painful bone metastases. Several
factors control this bone remodeling process includ-
ing parathyroid hormone-related protein (PTHrP),
receptor activator of NFkB and its ligand (RANK/
RANKL), osteoprotegerin (OPG), bone morphogenetic
proteins (BMPs), and transforming growth factor
b (TGF-b). At the bone metastatic site, osteoblasts
produce RANKL which binds to its receptor, RANK, on
osteoclast precursors causing them to mature and
absorb bone [10–12]. Bone resorption leads to release
of growth factors trapped in bone, including TGF-b.
(reviewed in references [13,14]). OPG is a soluble,
decoy RANKL receptor that blocks the ability of
RANKL to induce osteoclastogenesis [15]. Inhibition
of RANKL has been shown to inhibit establishment and
progression of PCa tumors in bone in murine models
[16–18]. These results indicate that RANKL inhibition
may be useful for the treatment of metastatic PCa
lesions in the bone.
Based on potential use of RANKL inhibition in PCa
and the need to enhance docetaxel-based chemo-
therapy regimens, we explored the effectiveness of
soluble RANK (RANK-Fc), a recombinant RANKL
inhibitor, as an adjuvant to docetaxel to reduce
progression of PCa in the bone. We found that the
combination of RANK-Fc and docetaxel reduced tumor
burden in bone greater than either treatment alone.
These data suggest that inhibition of RANKL can be a




C4-2B cells, isolated from bone-metastasizing
LNCaP cells [19,20], were maintained in T-medium
(80% DMEM-20% Ham’s F12 (GIBCO), 5 mg/ml
Insulin, 13.6 pg/ml triiodothyronine, 5 mg/ml trans-
ferrin, 0.25 mg/ml biotin, 25 mg/ml adenine (Sigma, St.
Louis, MO), 1penicillin/streptomycin and 10% FBS).
RANK-Fc
The RANK-Fc used in these studies was provided
by Amgen Inc. (Seattle, WA, USA) and contains
the murine extracellular domain of RANK (through
Pro213) fused to human immunoglobulin G1 (IgG1) Fc.
The RANK:Fc protein was produced in Chinese hamster
ovary (CHO) cells as previously described [17].
Animal Experiment
The effects of chemotherapy on PCa-derived cells in
bone were evaluated following direct injection into one
of two tibiae of male CB17 SCID mice (intratibial
injection) as described previously [16]. Briefly, mouse
hind limb is shaved, and the knee cap is located. Cells
(5 105) are injected in a volume of 50 ml into the tibia
percutaneously via the tibial crest into the marrow
cavity. To evaluate for effects of tumor growth in soft
tissues, 106 cells were injected to the right flank.
Two weeks after injection of cells, mice were injected
IP with docetaxel once a week (Taxotere, Aventis
Pharma, Bridgewater, NJ). Tumors were allowed to
grow for up to12 weeks at which time mice were
sacrificed. Evidence of tumor-induced bone change
was evaluated using radiography (Faxitron X-ray
Corp., Wheeling, IL) on Week 6 and at the end of
the study (Week 12). Tumor injected tibiae and
contralateral tibiae without tumors were removed,
fixed overnight in 10% PBS buffered formalin, and
transferred and stored in 70% ethanol. All animal
procedures were approved by the University of
Michigan Animal Care and Use Committee.
BoneAnalysis
Bone mineral densities were measured using
peripheral quantitative computed tomography (pQCT)
(Stratec, Dundas, Ontario, CA). pQCT scans from three
slices of the proximal metaphyses region were per-
formed to obtain trabecular bone densities. Following
pQCT analysis, tibiae were decalcified in Cal-Ex II
(Fisher Scientific, Hampton, NH) or EDTA, paraffin
embedded, and histological sections were stained with
hematoxylin and eosin (H&E). Histomorphometry
was performed on H&E stained sections and tumor
volume was quantitated using BioQuant Osteo II
(Bioquant Image Analysis Corporation, Nashville,
TN). Adjacent sections were stained for tartrate-
resistant acid phosphatase (TRAP) and area of TRAP
positivity was also quantified using BioQuant Osteo II
(Bioquant Image Analysis Corporation, Nashville, TN).
TRAP positive cells were counted along the endo-
cortical bone surfaces. The number of TRAP positive
cells is reported as osteoclasts/mm.
TumorMeasurements
The mice were monitored for body condition,
body weight, and subcutaneous tumor growth. Tumor
measurements using digital calipers were performed
weekly starting when the tumors became palpable.
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Tumor volumes were calculated using [(minimum
measurement)2 (maximum measurement)]/2 as pre-
viously described [21] Subcutaneous tumor volumes
and weights were also obtained at necropsy.
Statistics
When docetaxel dosing levels were compared, the
comparison of the number of mice who developed
tumors in each group was tested using a Fisher’s Exact
Test. Wilcoxon rank test compared subcutaneous
tumor volume and weight at necropsy between
5 mg/kg and PBS only.
Tumor and bone measures were analyzed between
the four groups in the RANK-Fc and docetaxel experi-
ment. Transformations were performed to attain a
centered distribution when needed. ANOVA models
were used to test all pair-wise comparisons. The
Tukey–Kramer adjustment was used to correct for
multiple comparisons.
RESULTS
Treatment of PCa patients with docetaxel has many
associated side effects. It follows that lowering the
dose administered may help minimize drug-induced
toxicities. However, dose reduction may be associated
with reduced anti-tumor efficacy. Thus, identification
of adjuvant agents to improve anti-tumor efficacy may
allow dose reduction without loss of overall tumor
kill. Accordingly, we tested the efficacy of a sub-
optimal dose of docetaxel in combination with a
RANKL inhibitor on subcutaneous PCa cell tumor
growth and PCa cell growth in bone. Accordingly, we
first identified a sub-optimal dose of docetaxel in our
animal model. SCID mice were inoculated sub-
cutaneously (SQ) and intratibially (IT) with C4-2B
PCa cells and given escalating doses of docetaxel once
a week for 10 weeks. Since 20 mg/kg in the mouse
correlates with the clinically used dose for human PCa
treatment [9], we chose doses lower than 20 mg/kg to
determine a sub-optimal dose of docetaxel; i.e., 0, 2.5, 5,
10, and 20 mg/kg. The schematic for the treatment
regimen is shown in Figure 1.
SQ tumor volumes were measured once a week and
final tumor weights were obtained at necropsy 1 week
after last treatment. Weekly intra-peritoneal injections
of docetaxel, even as low as 5 mg/kg, decreased SQ
tumor volume and tumor weight (Table I). Radio-
graphs of the injected tibiae were taken 2 weeks post-
initiation of docetaxel and during treatment to deter-
mine the progress of the lesions. The 2.5 and 5 mg/kg
doses were associated with partial reduction in PCa-
induced radiographic changes; whereas, the 10 and
20 mg/kg doses resulted in major reductions in
radiographic changes (Fig. 2A; Table I). We confirmed
this observation by histology, again finding evidence of
tumor growth in tibiae in the 20, 2.5, 5, and 10 mg/kg
dose groups but complete absence of tumor in the
20 mg/kg groups (Fig. 2B, Table I). H&E evidence
of tumors was concordant with PSA staining of
the tibiae. Taken together, these results demonstrate
that docetaxel had a differential effect on SQ tumors,
ablating them, versus tibial tumors, where residual
disease was still evident at equal dose levels.
No toxicity was observed for any of the dosage
groups; there was no change in animal weight or body
condition over the course of the experiment (data
not shown). Since the 5 mg/kg dose statistically
decreased SQ but not IT tumor incidence and burden
(Table I) and higher doses had greater anti-tumor
efficacy, the 5 mg/kg dose was chosen for further
analysis as the sub-optimal dose.
The next goal was to test if RANK-Fc possessed
adjuvant activity with docetaxel. However, to first
ensure that RANK-Fc would block RANKL in the mice,
we treated non-tumor bearing mice three times per week
with 250 mg/mouse RANK-Fc alone. This treatment
increased the bone mineral density, as measured by
pQ-CT (Fig. 3A), approximately 20% (Fig. 3B) while
maintaining bone area. Taken together, these data
indicate that RANK-Fc was working to diminish bone
resorption as described in the literature [17].
The efficacy of 5 mg/kg docetaxel in combination
with RANK-Fc, an anti-RANKL therapy, in our mouse
bone metastasis model was determined. The experi-
mental plan used is presented in Figure 3C. Briefly,
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Fig. 1. Schematicofexperimentalprocedureusedtodetermine the sub-optimaldoseofdocetaxel tobeusedinconjunctionwithRANK-Fc.
Briefly, 50 animalswere injectedwith1106C4-2BPCa cells subcutaneously and 5105C4-2BPCa cells intratibially.Twoweeks later, treat-
mentwas started.Animalsreceivedoneinjectionperweekof their appointeddoseofdocetaxel.Radiographsof tibiaewereobtainedhalf-way
through the treatmenttomonitor tibial lesions.Theanimalswerenecropsied12weeksafter tumorcellinjection.
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mice were injected IT with tumor cells and divided
into four groups (PBS/PBS, PBS/docetaxel, RANK-Fc/
PBS, and RANK-Fc/docetaxel). The weekly docetaxel
injections (5 mg/kg) were combined with three times
per week injections of RANK-Fc (250mg/mouse;
10 mg/kg), a dose we previously determined to be
effective toward bone lesions [17].
IT tumor incidence, as measured by radiography
(Fig. 3D and Table II), was not affected by docetaxel
alone as compared to the control PBS group. RANK-Fc
alone decreased IT tumor incidence by 50%; although
it was not a statistically significant drop, and the
combination of both docetaxel and RANK-Fc signi-
ficantly blocked development of IT tumors versus
treatment with PBS alone or docetaxel alone (Table II).
In concordance with the radiographic findings, histo-
morphometric measurement of tumor volume revealed
that docetaxel alone reduced IT tumor volume by
approximately 13%, RANK-Fc alone reduced tumor
volume by approximately 60%, which was a significant
reduction from the PBS alone group, and the combina-
tion of docetaxel and RANK-Fc reduced tumor volume
by approximately 70%, a significant reduction from
both the PBS alone group and the docetaxel alone
group, indicating that RANK-Fc had an adjuvant effect
with docetaxel (Table II). Of note, the bone volume was
The Prostate







IT tumors (% of animals)
Histological presence of
IT tumors (% of animals)
PBS only 1574 (2646) 3180 (4925) 80 100
2.5 mg/kg 183 (341) 550 (1060) 70 100
5.0 mg/kg 32 (67)a 2 (72)a,^ 80 100
10 mg/kg 0 (0)^ 16 (25)^ 30a 30a
20 mg/kg 0 (0)^ 0 (0)^ 0a 0a
By t-test using the Tukey–Kramer multiple comparisons adjustment, there were significant differences in tumor volume and tumor
weights between the control group, (PBS only) and the 5.0 mg/kg, 10 mg/kg, and 20 mg/kg groups. Standard Deviations are given in
parentheses.
aExcludes an outlier.
^P-value< 0.05 compared to PBS only.
Fig. 2. Radiological andhistological evidence of a tibial tumordoseresponse to increasingdoses of docetaxel.A:Radiographs of represen-
tative tibiaeforeachdoseandfora tumor freecontrolleg(non-injectedcontrol).Arrowsindicate theareasofbonedestruction(salinecontrol,
2.5,and5mg/kg).Theboneinthe10and20mg/kg treatmentgroupswasnotaffectedby tumorgrowth.B:H&EandPSAstainsofrepresentative
tibiae.PSAwasusedtoidentify tumorinthe tibiaeandisindicatedby thebrownstainseeninthelowerpanels. [Color figurecanbeviewedinthe
onlineissue,whichis availableatwww.interscience.wiley.com.]
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not significantly different between any of the groups
(Table II); whereas, the bone density was significantly
increased in the groups that received the RANK-Fc.
The tumor volume docetaxel/RANK-Fc group was
decreased compared to the PBS alone group, but the
decrease was not significant (P-value¼ 0.052). The
tumor volume to tissue volume ratios for the RANK-
Fc/docetaxel group were significantly different from
both the PBS alone and docetaxel alone groups
(Table II). Since we were comparing tumor to bone
The Prostate
Fig. 3. RANK-Fcprotectsbonedensity.A:SlicesthatwerescannedbypQ-CT. Thesmallboxintheleftpanelindicatesthetibia.Thereference
sliceandtheslicesmeasuredareindicatedonarepresentative tibia.B:Graphof theaveragebonedensityobtainedbypQ-CTof tibiaefromnon-
tumor bearingmice in the PBS/PBS or RANK-Fc/PBS group. *P< 0.001versus PBS/PBS (t-test).C: Schematic of experimental procedure to
determine the effect of RANK-Fc used in combinationwith 5mg/kg docetaxel.Briefly, 40 animalswere injected1106 C4-2B PCa cells sub-
cutaneously and 5105C4-2BPCa cells intratibially.Twoweeks later, treatmentwas started.Four treatmentgroupswere formed: PBS/PBS,
PBS/Doc,RANK-Fc/PBS,andRANK-Fc/Doc.RANK-FcorPBSinjectionsweregiventhreetimesperweek.DocetaxelorPBSwasinjectedonce
aweek IP in the opposite side than the RANK-Fc or PBS injections.Radiographs of tibiaewere obtained half-way through the treatment to
monitor tibial lesions.The animals were necropsied 12 weeks after tumor cell injection. Non-tumor bearing mice were also necropsied at
12weeks after the sameregimen of PBS/PBS or RANK-Fc/PBS treatment.D: Radiographs of representative tibiae for each treatmentgroup.
Arrows indicate tumor lesions (PBS/PBS,PBS/Doc, andRANK-Fc/PBS).RANK-Fc/Doc treatedanimals didnothave any lesions in their tibiae.
E:H&EandPSAstainsofrepresentative tibiae.PSAwasusedtoidentify tumorinthe tibiaeandisindicatedby thebrownstainseeninthelower
panels.Doc,docetaxel. [Color figurecanbeviewedin theonlineissue,whichis availableatwww.interscience.wiley.com.]
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volume ratios, we excluded measurements for all
animals that did not present with tibial tumors when
comparing bone, tissue, and tumor volumes. Tibiae
were also stained for PSA to identify the tumor,
which qualitatively demonstrated less PCa tumor with
the RANK-Fc and docetaxel/RANK-Fc combination
treatments compared to docetaxel alone (Fig. 3E).
Taken together, these data suggest that RANK-Fc
is an effective adjuvant to docetaxel for PCa bone
metastases.
To determine the effect of blocking RANKL on tumor-
induced osteoclastogenesis, paraffin-embedded sections
of each tibia were stained for TRAP, a marker for
osteoclasts (Fig. 4A). The TRAP staining was intense in
the saline control and docetaxel alone samples, very faint
in the RANK-Fc alone samples, and not detectable in the
combination RANK-Fc/Docetaxel animals. The number
of osteoclasts per IT tumor was determined, and, as a
measure of osteoclast activity, the amount of osteoclast-
mediated erosion was quantified. RANK-Fc alone or
RANK-Fc in combination with docetaxel reduced the
total number of endocortical osteoclasts (Fig. 4B) and the
eroded area (Fig. 4C) by 80–90% compared to the control
or to the docetaxel-alone groups. These data indicate that
blocking RANKL activity decreased osteoclast numbers
and activity suggesting that decreasing osteoclast activity
could contribute to decreasing tumor formation in the
bone in conjunction with docetaxel’s anti-tumor activity.
DISCUSSION
Docetaxel is the treatment of choice against soft
tissue PCa tumors; however, the side effects associated
with docetaxel treatment can be severe enough to
terminate the therapy. Since most advanced PCa
patients have bone metastasis, therapies that target
PCa bone metastasis were hypothesized to be effective
as adjunct therapies to sub-optimal doses of docetaxel.
Bone-targeted therapies, such as bisphosphonates,
added to the chemotherapy regimen for advanced
stage PCa have been effective for palliative care;
however, bisphosphonates have moderate to severe
toxicities associate with them and further work is
needed to improve their efficacy in combination with
chemotherapeutics toward bone metastases [22–24].
As an alternative to bisphosphonates for blocking
osteoclast activity, we evaluated RANKL inhibition as
an anti-osteoclastogenic agent for an adjuvant effect
with docetaxel. We found that blocking RANKL
enhanced the docetaxel’s anti-tumor efficacy.
RANK ligand (RANKL) is expressed on the surface
of osteoblasts and tumor cells and is sometimes
released as a soluble form. RANKL binds to the
receptor RANK. RANKL induces the maturation of
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hypothesized to be important in the seeding of PCa
cells into the bone microenvironment. OPG is a soluble
RANKL decoy receptor. It binds to and sequesters
RANKL so it cannot activate osteoclasts. Similar to
OPG, RANK-Fc is recombinant molecule consisting, in
part, of the extracellular component of RANK that
binds RANKL and blocks activation of osteoclasts [17].
The RANK/RANKL/OPG triad is a major part of
bone remodeling. Thus, it is currently being explored
as a target for bone metastasis therapy. For example,
OPG-Fc has been shown in Phase-I clinical trials to
reduce bone resorption as well as bisphosphonates,
which are the gold standard of treatment [37–39]. Also,
denosumab, a fully human monoclonal antibody to
RANKL (Amgen, Inc., Thousand Oaks, CA), reduced
bone resorption in osteoporosis [40] and is now in
Phase II and Phase III clinical trials for treatment of
bone metastases. These data suggest that targeting the
RANK/RANKL/OPG triad is a selective way of
reducing the effects of bone resorption in skeletal
metastases.
Although docetaxel is the treatment of choice for
PCa, once men develop bone metastasis, docetaxel
efficacy declines. Based on their work with murine
models both Brubaker et al. [25] and Quinn et al. [26]
suggest that docetaxel by itself is not able to abolish
osteoblastic tumors because it cannot enter the bone.
However, their work suggests that docetaxel can work
synergistically with the bisphosphonate zoledronic
acid to suppress growth of tumors in bone. We
argue that docetaxel could enter the osteoblastic
environment since, in our study, a dose of 10 mg/kg
greatly decreased the number and size of osteoblastic
IT tumors, and a 20 mg/kg dose completely abolish-
ed IT tumors. However, lower doses of docetaxel
(5 mg/kg) induced a response on SQ tumor size but
no effect on IT tumors. Taken together, these results
suggest that although docetaxel can kill PCa cells in the
bone, the bone provides a protective microenviron-
ment for PCa tumors. This may be due to differences in
bioavailablity of drug or actual changes in the PCa cells
due to growth factors and other tumor active sub-
stances in the bone. It should be noted that Brubaker
et al. [25] used LuCaP 23.1 cells for their experiments
and found it was necessary to use much higher doses of
docetaxel (20 mg/kg) than we found were effective.
This effect could be the result of the more intense
osteoblastic reaction obtained with LuCaP 23.1 cells
compared to C4-2B tumors growing in tibiae. Regard-
less of the mechanism, our results indicate that PCa
bone metastases are more resistant to docetaxel than
soft tissue metastases and thus it would be beneficial to
identify adjuvants to enhance docetaxel-mediated
tumor killing in bone.
Kim et al. [41] have suggested that zoledronic acid
cooperates with paclitaxel. Their results show only
a minimal additive effect with the two drugs. The
enhanced effect of zoledronic acid with paclitaxel is
only seen when STI571 is also present, indicating, at
least by their data, that PDGFR plays a role in bone
metastasis and its inhibition is required in the case of
zoledronic acid to observe an additive effect with
The Prostate
Fig. 4. RANK-Fc plus docetaxel decreases osteoclast numbers.
The trabecular regionwas defined as the top15% of the tibia distal
to the growth plate and the osteoclasts lining the endocortical
bone were quantified. A: RepresentativeTRAP staining for each
treatment is shown. Insets are increased magnification of TRAP
staining in each sample. Purple indicates a positive TRAP stain.
Arrows indicate areas of TRAP-positive staining.B:The number of
osteoclasts per millimeter endocortical bone is shown.*P< 0.05
versus PBS/PBS;#P< 0.05 versus PBS/Doc.C: Amount of eroded
endocortical bone surface as a measure of osteoclast actvity
is shown. *P< 0.05 versus PBS/PBS; #<0.05 versus PBS/Doc.
Doc, docetaxel. [Color figure can be viewed in the online issue,
whichis availableatwww.interscience.wiley.com.]
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paclitaxel. In contrast, our report demonstrates that
inhibition of osteoclast activity with RANK-Fc is
sufficient to provide an adjuvant effect with docetaxel.
The difference in the results may be accounted for
by the drug differences; we used a different taxane
than both Kim et al. [41] and Brubaker et al. [25] and
RANK-Fc inhibits overall osteoclast activity via a
different mechanism than bisphosphonates. Inhibition
of RANKL reduces osteoclast formation; whereas,
bisphosphonates promoters osteoclast apoptosis. This
difference in anti-osteoclast activity could potentially
account for the observed difference in adjuvant
activity. Brubaker et al. [25] showed that the bone
volume to tissue volume ratio increased with both
zoledronic acid and with the LuCaP 23.1 tumor, suggest-
ing that as the tumor shrank, there was less space
for normal marrow to fill. Since the LuCaP 23.1 cells
form a highly osteoblastic tumor, the increase in
bone volume may not be attributed to either the
zoledronic acid or the tumor shrinkage but rather
caused by the osteoblastic activity of the tumor. We
show that the bone volume to tissue volume ratio does
not change significantly when RANK-Fc is used. Since
we used a cell line that produces a less osteoblastic
tumor than LuCap 23.1, C4-2B, we can postulate that
the reduction in tissue volume as seen in the Brubaker’s
paper may be attributed to the osteoblastic activity
of LuCaP 23.1 cells; however, we did use a different
adjuvant.
Recent results from Hall et al. [27–29] suggest that in
order for PCa to grow in bone, the tumor must first elicit
an osteoclastic response then cause an osteoblastic
response as the tumor establishes in bone, suggesting
that blocking the osteoclastic response should block
osteoblastic tumor establishment in bone. Therefore,
we tested the effects of lower doses of docetaxel
in combination with a novel therapy, RANK-Fc, an
inhibitor which selectively inhibits osteoclast dif-
ferentiation, activation, and survival. We found that
the combination of a sub-optimal dose of docetaxel and
RANK-Fc had an additive effect on diminishing PCa
growth in bone.
The mechanism underlying the anti-RANKL therapy
effectiveness is unclear. Specifically, RANK-Fc blocks
osteoclast-mediate bone resorption in vivo, but what
effect this has on the establishment of bone metastasis is
still debated [28,29]. Osteoclast activity could contribute
to cancer growth in bone through debulking the bone or
release of growth factors from the bone microenviron-
ment, thus, providing a favorable environment for the
cancer cells to grow. This possibility is in agreement with
previous reports that bone remodeling promotes cancer
growth [30,31]. Therefore, blocking osteoclast activity
may inhibit release of growth factors, thus, making the
bone microenvironment inhospitable for tumor growth.
However, since there is no significant increase in bone
volume, either due to the drug or to the osteoblastic
nature of the tumor, but there is a significant increase in
bone density, our data suggest that an increase in bone
density accompanies the decrease in tumor growth
when RANK-Fc is present and that the osteoblastic
nature of the C4-2B tumors does not decrease the normal
tissue area. Therefore, RANK-Fc treatment promotes an
anti-tumor effect in the bone and an increase in bone
density. Taken together, that RANK-Fc may be a useful
adjuvant for docetaxel PCa therapy.
The data presented here imply that RANKL inhibi-
tion may have a dual effect in PCa. Men with PCa
that undergo hormonal therapy develop osteoporosis,
likely due to the hormonal deprivation [32–34]. The
observation that inhibition of RANKL increased bone
density supports previous findings that RANK-Fc
protects against osteoporosis [17,35,36]. The adjuvant
effect with docetaxel indicates that RANK-Fc can target
PCa through both inhibiting treatment-induced osteo-
porosis as well as tumor-induced bone destruction.
Our data suggest that RANK-Fc is a viable adjuvant
therapy for docetaxel. Even though bisphosphonates
are now widely used to reduce bone pain and skeletal-
related events, such as bone fracture, in PCa, they can
induce osteonecrosis of the jaw [42,43] as a side effect
of the treatment. Also, OPG can block cancer cell
apoptosis by binding to TRAIL [44–46], thus it may not
be a clinically viable anti-cancer therarpy. These data
taken with the data presented here indicate that
antagonists which selectively bind and inhibit RANKL
should be studied clinically as an option for adjuvant
therapy.
In summary, the data presented here indicate that
inhibition of RANKL has an additive effect with
docetaxel for skeletal PCa lesions. These results suggest
that RANKL inhibition should be evaluated for
adjuvant activity with docetaxel in clinical trials for
advanced PCa.
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